GlaxoSmithKline is considering taking its HIV joint venture public, tersely dropping hints of an IPO for ViiV Healthcare as it lays out plans to again slash R&D costs and refocus its business.
A few things struck us while gathering this year's class of the Fierce 15, our 12th annual take on some of the most noteworthy private biotech upstarts making headway these days. First, you'll find a higher than usual accumulation of early-stage companies in the group. And it's not hard to see why. Once the IPO window opened in early 2013, we saw a whole slew of earlier winners jump through--many like bluebird and Agios winning some extraordinary returns for investors. By the end of last year we were beginning to see plenty of other newcomers make the move as well, definitely winnowing out the number of more advanced companies to select from.
Carving out a successful career in biopharma isn't easy, for men or women. The failure rate of experimental drugs is astronomically high. And just because a company wins an approval is no guarantee of success, particularly in this increasingly challenging market. At the same time, though, it was no great feat to find 15 women who have been doing some amazing things. Check out the special report >>
Tuesday's executive breakfast in Boston will feature some of the best and brightest people in drug development. Nick Leschly, head of bluebird bio, which has been adding genetic engineering technology while pioneering gene therapies, is on board. He'll be joined by Jason Gardner, who recently moved to Boston to set up a drug and talent scouting group for GlaxoSmithKline. David Schenkein, the head of closely watched Agios and Jim Burns, who heads Sanofi's R&D ops in its growing Boston hub, are joining the conversation. And J.C. Gutierrez-Ramos from Pfizer--which has been racing to the regulators with palbociclib--will also be on stage. Read more >>
It's better to be lucky than smart, but to be among the best life sciences investors it helps to be both. We've compiled a list of public company investors who have managed to outperform the NASDAQ Biotechnology Index (NBI), mostly driven by their participation in some of the top biotech performers this year.
Biotech blew up in 2014. In the first quarter alone, 29 life sciences companies went public, bringing in $2.1 billion. By the middle of the year, 2014 had proven more lucrative than its predecessor, as seemingly every outfit with a small molecule and an on-file S-1 found underwriters willing to carry it to market. And thus this list is our somewhat subjective ranking of the year's most successful biotech IPOs, for which we took a look at pricing compared to range, overall amount raised and postpricing performance. Read the full report >>
POPULAR COMMENT THREADS
Welcome to the hall of shame, where blockbuster drug projections go to die. Here you'll find some drugs that clearly should never have wound up in Phase III to begin with, a few that were actually steered back to the clinic in a doomed attempt to mine something positive after wasting millions on clinical trials and a couple of notable exceptions that may have helped advance the field by exploring the outer limits of new drug technology. Read more >>
They're building a new home for John Reed and Roche's pRED research group in Basel--and the pharma giant is thinking big. Roche said today that it is committing $1.8 billion to build a new research center in Switzerland that will encompass four new office and lab buildings to house 1,900 R&D staffers.
Regulus Therapeutics, at work on a microRNA approach to hepatitis C, watched its shares skyrocket on positive early data for its lead candidate, which significantly reduced viral loads with a single dose.
Hedge fund manager Daniel Loeb is lending his voice to the chorus of investors who believe Amgen would do better as two companies. And his firm, Third Point, has upped its stake in the Big Biotech, giving him a bigger stage from which to pressure executives.
With several players now in the race toward a vaccine for Ebola, Johnson & Johnson says it is ramping up development efforts toward its own program, devoting $200 million to the cause.
Proteon Therapeutics priced its IPO below its expected range, clearing $61 million to pay the way for its investigational vascular drug.
From Our Sister Sites
To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.
GlaxoSmithKline's vaccines unit will be getting a new look come next year, when it's expected to absorb the bulk of Novartis' vaccines lineup it bought for $7.1 billion back in April. It'll have some new management, too, with Moncef Slaoui in the chairman's role. And judging from the pharma giant's Q3 results, some change for the unit could be a good thing.